Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

LY2140023 – Treatment of Schizophrenia

Drug (Brand/Generic)

LY2140023

Company/Licensee

Eli Lilly

Therapy Class

Glutamate agonist

Product Description

Reduces presynaptic release of glutamate

Current Indication

Treatment of schizophrenia

Market Sector

CNS

Development Status

Phase III
Expand

Go Top